<DOC>
	<DOCNO>NCT01276717</DOCNO>
	<brief_summary>This phase I study carfilzomib combination vorinostat patient relapsed/refractory B-cell lymphoma . Combination therapy proteosome inhibitor PR-171 HDAC inhibitor highly synergistic primary DLBCL cell , class drug also synergize powerfully induce cell death bortezomib-resistant cell . The purpose study see vorinostat combine carfilzomib safely find recommended phase II dose .</brief_summary>
	<brief_title>Study Carfilzomib Vorinostat Relapsed Refractory Lymphoma</brief_title>
	<detailed_description>Study Drugs : Vorinostat , class I/II pan-histone deacetylase inhibitor ( HDACI ) , first approve agent og class basis activity refractory cutaneous T-cell Lymphoma . Lethal mechanisms include anti-apoptotic protein down-regulation , up-regulation proapoptotic protein , induction ROS , death receptor up-regulation , disruption chaperone function DNA-repair protein . Carfilzomib , irreversible proteasome inhibitor epoxyketone class exhibit high level selectivity proteosome . This agent induce dose- time-dependent inhibition proliferation , ultimately leading apoptosis . Study Drug Administration : If find eligible take part study : - Vorinostat PO twice daily Days 1 , 2 , 3 , 8 , 9 , 10 , 15 , 16 17 . - Daily Carfilzomib 30 minute infusion Days 1 , 2 , 8 , 9 , 15 , 16 . - Administer first daily dose vorinostat prior carfilzomib Days 1 , 2 , 8 , 9 , 15 , 16 - Cycle repeat every 28 day , 13 cycle . Carfilzomib give 20mg/m2 day 1 2 cycle 1 , escalate high dose indicated schema day 8 cycle 1 thereafter . Carfilzomib treatment do early morning minimum 6 hour observation period infusion . For patient good tolerability carfilzomib first cycle , observation period 2 hour recommend . A minimum 16 hour separate dos carfilzomib , day 1 dose may give afternoon day 2 dose morning cycle 2 subsequent cycle patient tolerate drug well . If two 6 patient tolerate initial dose 20 mg/m2 carfilzomib day 1 &amp; 2 follow 27 mg/m2 carfilzomib subsequent dose 200 mg/day bid vorinostat , next patient dose reduce 20 mg/m2 carfilzomib 100 mg/day bid vorinostat . Study Visits : - Baseline within 4 week Cycle 1 Day 1 . - CT physical exam . - Bone marrow need follow disease status . - PET recommend require . To document complete response ( CR ) , PET REQUIRED . - Optional research tumor biopsy . - Peripheral blood obtain PD prior initiation treatment 48 hour +/- 6 hour receive first dose Carfilzomib , Off Study . - End Treatment Restaging take place 6-8 week completion treatment include assessment physician , lab , tumor response evaluation . - After completion Restaging exam , Follow exam take place every 6 month 2 year annually disease progression initiation another treatment . - An Off Study visit take place time disease progression initiation another treatment , include assessment physician , tumor response evaluation , lab , final PD sample , patient 's consent .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Histologically confirm Bcell lymphoma , exclude CLL ( Chronic Lymphocytic Leukemia ) , recurrent refractory least one prior therapy potentially curative therapy available . Age ≥ 18 year ECOG Performance Status ( PS ) ≤ 2 Laboratory parameter SLL , lymphocyte count &lt; 5,000/µL Absolute neutrophil count ≥ 1000/µL Platelets ≥ 75,000/µL Creatinine ≤ 1.5x upper limit normal calculated creatinine clearance &gt; 40mL/min AST , ALT ≤ 2.5 x upper limit normal ( ULN ) Bilirubin ≤ 2.0 mg/mL Serum potassium ≥ 3.5 mEq/L serum magnesium ≥ 1.7 mEq/dL ( electrolyte may correct supplementation ) . PT &lt; 1.5 x ULN PTT &lt; 1.2 x ULN ( unless receive therapeutic anticoagulation ) . Patient , investigator 's opinion , willing able comply protocol requirement offer write informed consent . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , oral injectable hormonal method ; barrier method intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . History brain metastasis include leptomeningeal metastasis . Chemotherapy radiotherapy within 3 week prior enter study . Prior histone deacetylase inhibitor cancer treatment . Concurrent treatment investigational agent cancer treatment . Unable take oral medication . Active ischemic heart disease congestive heart failure . If suspicion cardiac disease , leave ventricular ejection fraction ( LVEF ) must ≥ 45 % , otherwise study evaluate EF require . Persistent blood pressure ( BP ) ≥ 160/95 ( three separate reading different day ) . History allergic reaction attribute compound similar chemical biological composition carfilzomib vorinostat . Known clinical significant infection include infection human immunodeficiency virus ( HIV ) , active hepatitis B C , require treatment . Serious medical psychiatric illness likely interfere patient participation . Pregnant nursing . Confirmation woman pregnant must establish negative serum pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . No prior allogeneic stem cell transplant . Patients schedule type stem cell transplant within 4 week treatment . Patients valproic acid epilepsy enroll , provide stop drug least 30 day prior enrollment stable , effective dose alternative antiseizure medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>